Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer

Exclusion Criteria

• •All Patients must have Measurable Disease
• •* Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension; the longest diameter of measurable lesions must be \>= 20 mm with conventional techniques or \>= 10 mm with spiral CT scan; lesions that are not considered measurable include the following:
• •* Bone lesions
• •* Leptomeningeal disease
• •* Ascites
• •* Pleural/pericardial effusion
• •* Abdominal masses that are not confirmed and followed by imaging techniques
• •* Cystic lesions
• •* Tumor lesions situated in a previously irradiated area
• •ECOG Performance Status 0-1
• •No significant cardiac disease, including:
• •Congestive heart failure that meets New York Heart Association (NYHA) class III/IV definitions, history of myocardial infarction within one year of study entry, uncontrolled dysrhythmias, or poorly controlled angina
• •History of serious ventricular arrhythmia (VT or VF, \>= 3 beats in a row), QTc \>= 500 msec, or LVEF =\< 40% by MUGA
• •Evidence of left ventricular hypertrophy by echocardiographic criteria or by EKG criteria (Cornell voltage criteria):
• •For Men: S in V3 plus R in aVL \> 2.8 mV (28mm) For Women: S in V3 + R in aVL \> 2.0 mV (20mm)
• •Patients may not be co-medicated with an agent that causes QTc prolongation
• •No current treatment with potassium wasting diuretics (e.g., hydroclorothiazide); patients on such diuretics should be switched to a potassium sparing diuretic or another antihypertensive medication prior to registration
• •Granulocytes \>= 1,500/μl
• •Platelets \>= 100,000/μl
• •Total Bilirubin =\< 1.5 x ULN
• •AST (SGOT) =\< 2.5 x ULN
• •Creatinine ≤1.5 x ULN OR Calculated Creatinine Clearance \>= 60 ml/min
• •Non-pregnant and non-nursing because of significant risk to the fetus/infant; the effects of depsipeptide on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because histone deacetylase inhibitors are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to and for the entire duration of participation and for at least 6 weeks after completion of treatment